Bimzelx (bimekizumab)

pCPA File Number: 21821

Negotiation Status:

Concluded with an LOI

Indication(s):

Psoriasis, moderate to severe plaque

Sponsor/Manufacturer:

UCB Canada Inc.

CDA-AMC Project Number:

SR0698-000

pCPA Engagement Letter Issued:

2022-09-13

Negotiation Process Concluded:

2022-12-09